Top

Published in:

01-06-2008 | Review

The history of cytomegalovirus and its diseases

Author: Monto Ho

Published in: Medical Microbiology and Immunology | Issue 2/2008

Abstract

Intranuclear inclusions typical of cytomegalovirus infections were first noticed in 1881 by German scientists who thought they represented protozoa. After viruses were grown in cell cultures, Weller, Smith and Rowe independently isolated and grew CMV from man and mice in 1956–1957. Antibodies in 30–100% of normal adults indicate not only a past infection, but the presence of a present latent infection. The presence of CMV DNA in tissues and most organs surveyed indicates the ubiquity of latent infection. CMV disease requires the virus and some deficiency of immunity such as occurs in the immature fetus, in AIDS, and in transplant patients on immunosuppressive drugs. Antiviral agents can inhibit CMV replication but they cannot prevent or cure latent infections. A pharmacological approach using the many leads in understanding latency is needed.

Ribbert H (1904) Ueber protozoenartige Zellen in der Niere eines syphilitischen Neugeborenen und in der Parotis von Kindern. Zbl All Pathol 15:945–948

Jesionek A, Kiolemenoglou B (1904) Ueber einen Befund von protozoenartigen Gebilden in den Organen eines hereditar-luetischen Foetus. Muenchner Med Wochenschr 51:1905–1907

Lòwenstein C (1907) Ueber protozoenartige Gebilde in den Organen von Kindern. Zbl Allg Pathol 18:513–718

Von Glahn WC, Pappenheimer AM (1925) Intranuclear inclusions in visceral disease. Am J Pathol 1:445–465

Lipschuetz B (1921) Untersuchungen ueber die Aetiologie der Krankheiten der Herpes genitalis. Arch Dermatol Syph 136:428–482CrossRef

Farber S, Wolbach S (1932) Intranuclear and cytoplasmic inclusions (protozoan-like bodies) in the salivary glands and other organs of children. Am J Pathol 8:123–135PubMedPubMedCentral

Wyatt JP, Saxton J, Lee RS, Pinkerton H (1950) Generalized cytomegalic inclusion disease. J Pediatr 36:271–294PubMedCrossRef

Fetterman GH (1952) A new laboratory aid in the diagnosis of inclusion disease of infancy. Clin Pathol 22:424–425

Minder WH (1953) Die Aetiologie der Cytomegalia infantum. Schweiz Med Wochenschr 83:1180–1182PubMed

10.

Enders JF, Weller TH, Robbins FC (1949) Cultivation of the lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109:85–87PubMedCrossRef

11.

Weller TH, Macauley JC, Craig JM, Wirth P (1957) Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. Proc Soc Exp Biol Med 94:4–12PubMedCrossRef

12.

Smith MG (1956) Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SVG) disease. Proc Soc Exp Biol Med 92:424–430PubMedCrossRef

13.

Rowe WP, Hartley JW, Waterman S et al (1956) Cytopathogenic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids. Pro Soc Exp Biol Med 92:418–424CrossRef

14.

Weller TH (1953) Serial propagation in vitro of agents producing inclusion bodies derived from varicella and herpes zoster. Proc Soc Exp Biol Med 83:340–346PubMedCrossRef

15.

Weller TH (1970) Cytomegalovirus: the difficult years. J Infect Dis 122:532–539PubMedCrossRef

16.

Weller TH, Hanshaw JB, Scott DE (1960) Serologic differentiation of viruses responsible for cytomegalic inclusion disease. Virology 108:843–868

17.

Boppana SB, Rivera LB, Fowler KB et al (2001) Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 344:1366–1371PubMedCrossRef

18.

Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R (2004) Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 39:233–239PubMedCrossRef

19.

Cha TA, Tom E, Kemble GW et al (1996) Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 70:78–83PubMedPubMedCentralCrossRef

20.

Krech U, Jung M, Jung F (1971) CMV infections in man. S. Karger, Basel, 124 pp

21.

Reynolds DW, Stagno S, Hosty TS et al (1973) Maternal cytomegalovirus excretion and perinatal infection. N Engl J Med 289:1–5PubMedCrossRef

22.

Stagno S, Reynolds DW, Pass RF, Alford CA Jr (1980) Breast milk and the risk of cytomegalovirus infection. N Engl J Med 302:1073–1074PubMedCrossRef

23.

Numazaki Y, Yano N, Morizuka T et al (1970) Primary infection with human cytomegalovirus: virus isolation from healthy infants and pregnant women. Am J Epidemiol 91:410–417PubMedCrossRef

24.

Lamb SB, Stern H (1966) Cytomegalovirus mononucleosis with jaundice as presenting sign. Lancet 2:1003–1007PubMedCrossRef

25.

Chretien JH, McGinnis CG, Muller A (1977) Venereal causes of cytomegalovirus mononucleosis. JAMA 238:1644–1645PubMedCrossRef

26.

Handsfield HH, Chandler SH, Caine VA et al (1985) Cytomegalovirus infection in sex partners: evidence of transmission. J Infect Dis 151:344–348PubMedCrossRef

27.

Drew WL, Sweet ES, Miner RC et al (1984) Multiple infections by cytomegalovirus in patients with acquired immune deficiency syndrome: documentation by southern blot hybridization. J infect Dis 155:891–896

28.

Coutinho RA, Van Dillen PW, Van Lent PA et al (1984) Infection with cytomegalovirus in homosexual men. Br J Vener Dis 60:249–252PubMedPubMedCentral

29.

Collier AC, Meyers JD, Corey L et al (1987) Cytomegalovirus infection in homosexual men. Am J Med 82:593–600PubMedCrossRef

30.

Mintz L, Drew WL, Miner RC, Braff EH et al (1983) Cytomegalovirus infections in homosexual men. Ann Intern Med 99:326–329PubMedCrossRef

31.

Reddehase MJ (2006) Cytomegaloviruses: molecular biology and immunology, Caister Academic Press, Norfolk, 619 pp

32.

Ho M, Suwansirikul S, Dowling JN et al (1975) The transplanted kidney as a source of cytomegalovirus infection. New Engl J Med 293:1109–1112PubMedCrossRef

33.

Ho M (1991) Cytomegalovirus: biology and infection, 2nd edn, Chap 13. Plenum, New York, pp 249–300

34.

Hendrix RM, Wagenaar M, Slobbe RL, Bruggeman CA (1997) Widespread presence of cytomegalovirus DNA in tissues of healthy trauma victims. J Clin Pathol 50:59–63PubMedPubMedCentralCrossRef

35.

Sinclair J, Sissons P (1996) Latent and persistent infections of monocytes and macrophages. Intervirology 39:293–301PubMedCrossRef

36.

Pereira L, Maidji E, McDonagh S, Tabata T (2006) Routes of human CMV transmission and infection at the uterine-placental interface. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology, Chap 3. Caister Academic Press, Norfolk, pp 29–48

37.

Klemola E, Kaariainen L (1965) Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis. Br Med J 2:1099–1102PubMedPubMedCentralCrossRef

38.

Rinaldo CR, Levin MJ, Carney WP et al (1979) Interaction of lymphocytes with cytomegalovirus. In: Proffit MR (ed) Virus-lymphocyte interactions: implications for disease. Elsevier-North Holland, Amsterdam, pp 267–282

39.

Saltzman RL, Quirk MR, Jordan MC (1988) Disseminated cytomegalovirus infecton. Molecular ananlysis of virus and leukocyte interactions in viremia. J Clin Invest 81:75–81PubMedPubMedCentralCrossRef

40.

Diosi P, Moldovan E, Tomescu N (1969) Latent cytomegalovirus infection in blood donors. Br Med J 4:660–662PubMedPubMedCentralCrossRef

41.

Armstrong JA, Tarr GC, Ho M et al (1976) Cytomegalovirus infection with in children undergoing open-heart surgery. Yale J Biol Med 49:83–91PubMedPubMedCentral

42.

Ho M (1991) Cytomegalovirus: biology and infection, 2nd edn. Plenum, New York, p 177, 440 pp

43.

Yeager AS, Grumet FC, Hafleigh EB et al (1981) Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 98:281–287PubMedCrossRef

44.

Bowden RA, Sayers M, Flournoy N et al (1986) Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 314:1006–1010PubMedCrossRef

45.

Demmler GJ (1991) Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 13:315–329PubMedCrossRef

46.

Gallant JE, Moore RD, Richman DD et al (1992) Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 166:1223–1227PubMedCrossRef

47.

Verbraak FD, Boom R, Wertheim-van Dillen PM et al (1999) Influence of highly active antiretroviral therapy (HAART) on the development of CMV disease in HIV positive patients at high risk for CMV disease. Br J Ophthalmol 83:1186–1189 PubMedPubMedCentralCrossRef

48.

Cohen BA, McArthur JC, Grohman S et al (1993) Neurologic prognosis of cytomegalovirus polyradiculomyelopathy in AIDS. Neurology 43:493–499PubMedCrossRef

49.

Holland NR, Power C, Mathews VP et al (1994) Cytomegalovirus encephalitis in acquired immunodeficiency syndrome (AIDS). Neurology 44:507–514PubMedCrossRef

50.

Haymaker W, Girdany BR, Stephens J et al (1954) Cerebral involvement with advanced periventricular calcification in generalized cytomegalic inclusion disease in the newborn. J Neuropathol Exp Neurol 13:562–586PubMedCrossRef

51.

Price TA, Digioia RA, Simon GL (1992) Ganciclovir treatment of cytomegalovirus ventriculitis in a patient infected with human immunodeficiency virus. Clin Infect Dis 15:606–608PubMedCrossRef

52.

Bartlett JG, Laughon B, Quinn TC (1988) Gastrointestinal complications of AIDS. In: DeVita VT, Hellman S, Rosenberg SA (eds) AIDS, etiology, diagnosis, treatment and prevention, 2nd edn. Lippincott, Philadelphia, pp 227–244

53.

Pereyra F, Rubin RH (2004) Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 17:357–361PubMedCrossRef

54.

Ho M (1991) Cytomegalovirus: biology and infection, 2nd edn. Plenum, New York, p 250, 440 pp

55.

Ho M (1991) Cytomegalovirus: biology and infection, 2nd edn. Plenum, New York, p 251, 440 pp

56.

Ho M (1991) Cytomegalovirus: biology and infection, 2nd edn. Plenum, New York, p 257, 440 pp

57.

Meyers JD, Flournoy N, Thomas ED (1986) Risk factors for cytomegalovirus infection after human marrow transplant. J Infect Dis 153:478–488PubMedCrossRef

58.

Peterson PK, Balfour HH, Marker SC et al (1980) Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine 59:283–300PubMedCrossRef

59.

Ho M (1987) Infection and organ transplantation. In: Gelman S (ed) Anesthesia and organ transplantation. WB Saunders, Philadelphia, pp 49–60

60.

Dummer JS, Montero CG, Griffith BP et al (1986) Infection in heart-lung transplant recipients. Transplantation 41:725–729PubMedCrossRef

61.

Rubin RH, Tolkoff-Rubin NE, Oliver D et al (1985) Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation 40:243–249PubMedCrossRef

62.

Chou S, Norman DJ (1985) Effect of OKT3 antibody therapy on cytomegalovirus reactivation in renal transplant recipients. Transplantation Proc 17:2755–2756

63.

Starzl TE, Fung J, Venkataramman R et al (1989) FK 506 for liver, kidney, and pancreas transplantation. Lancet 2:1000–1004PubMedPubMedCentralCrossRef

64.

Thomason AW (1990) FK-506-how much potential? Immunol Today 11:6–9

65.

Spector SA, Davis JL, Singh N (2006) Cytomegalovirus. http://www.antimicrobe.org/12rev.asp

66.

Cheng YC, Huang ES, Lin JC et al (1983) Unique spectrum of activity of 9-[(1,3-dihydro-2-propoxy)methyl]guanine against herpes simplex type 1. Proc Natl Acad USA 80:2767–2770CrossRef

67.

Felsenstein D, D’Amico DJ, Hirsch MS et al (1985) Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann Intern Med 103:377–380PubMedCrossRef

68.

Felsenstein D, D’Amico DJ, Hirsch MS et al (1985) Treastment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine and high-dose corticosteroids. Ann Intern Med 105:214–215

69.

Bach MC, Bagwell SP, Knapp NP et al (1985) 9-(1,3dihydroxy-2-propoxymethyl)guanine for cytomegalovirus infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 103:381–384 PubMedCrossRef

70.

Reed EC, Bowden RA, Dandliker PS et al (1988) Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 109:783–78PubMedCrossRef

71.

Lazzarotto T, Dal Monte P, Landini MP (1996) Recent advances in the diagnosis of cytomegalovirus infection. Ann Biol Clin 54:259–265

72.

Spector SA, Merrill R, Wolf D et al (1992) Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol 30:2359–2365PubMedPubMedCentralCrossRef

73.

Paya CV (2001) Prevention of cytomegalovirus disease in recipients of solid organ transplants. Clin Infect Dis 32:596–603PubMedCrossRef

74.

Singh N (2005) Late-onset cytomegalovirus disease as a significant complication in organ transplant recipients receiving antiviral prophylaxis: a call to heed mounting evidence. Clin Infect Dis 40:704–708PubMedCrossRef

Title: The history of cytomegalovirus and its diseases
Author: Monto Ho
Publication date: 01-06-2008
Publisher: Springer Berlin Heidelberg
Published in: Medical Microbiology and Immunology / Issue 2/2008
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-007-0066-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The history of cytomegalovirus and its diseases

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

Refinement of strategies for the development of a human cytomegalovirus dense body vaccine

The salivary glands as a privileged site of cytomegalovirus immune evasion and persistence

Differences between mouse and human cytomegalovirus interactions with their respective hosts at immediate early times of the replication cycle

Role of the cytomegalovirus major immediate early enhancer in acute infection and reactivation from latency

Correlation of dendritic cell maturation and the formation of aggregates of poly-ubiquitinated proteins in the cytosol

Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page